364 related articles for article (PubMed ID: 30885354)
21. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Sepesi B; Gomez DR; Antonoff MB;
J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1497-1504.e2. PubMed ID: 32331820
[TBL] [Abstract][Full Text] [Related]
22. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
23. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
[TBL] [Abstract][Full Text] [Related]
25. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.
Petrelli F; Ghidini A; Cabiddu M; Tomasello G; De Stefani A; Bruschieri L; Vitali E; Ghilardi M; Borgonovo K; Barni S; Trevisan F
Lung Cancer; 2018 Dec; 126():194-200. PubMed ID: 30527187
[TBL] [Abstract][Full Text] [Related]
26. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
27. Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
Romine PE; Martins RG; Eaton KD; Wood DE; Behnia F; Goulart BHL; Mulligan MS; Wallace SG; Kell E; Bauman JE; Patel SA; Vesselle HJ
BMC Cancer; 2019 Jan; 19(1):70. PubMed ID: 30642285
[TBL] [Abstract][Full Text] [Related]
28. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
[TBL] [Abstract][Full Text] [Related]
29. Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.
Aggarwal C; Cohen RB; Yu E; Hwang WT; Bauml JM; Alley E; Evans TL; Langer CJ
Clin Lung Cancer; 2018 Mar; 19(2):157-162. PubMed ID: 29129435
[TBL] [Abstract][Full Text] [Related]
30. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
[TBL] [Abstract][Full Text] [Related]
33. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
[TBL] [Abstract][Full Text] [Related]
34. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
35. Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy.
Miyawaki T; Wakuda K; Kenmotsu H; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ono A; Naito T; Murakami H; Notsu A; Mori K; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Cancer Sci; 2021 Jan; 112(1):359-368. PubMed ID: 33098119
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
37. Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes.
Dudani S; Zhu X; Yokom DW; Yamada A; Ho C; Pantarotto JR; Leighl NB; Zhang T; Wheatley-Price P
Clin Lung Cancer; 2018 Jan; 19(1):e11-e18. PubMed ID: 28711384
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
40. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
